Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio

Fineline Cube Jul 17, 2026
Company Drug

Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma

Fineline Cube Jul 17, 2026
Company Deals

Tower Cold Chain Expands into China with Partnership with Tower & Winner Solutions

Fineline Cube Dec 20, 2023

Tower Cold Chain, a UK-based specialist in pharmaceutical container solutions, has announced a partnership with...

Company Deals

Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences

Fineline Cube Dec 20, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option...

Company Deals

China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer

Fineline Cube Dec 19, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing...

Company Deals

Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market

Fineline Cube Dec 19, 2023

Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and...

Company Drug

European Commission Expands Keytruda Indications for Advanced Cancer Treatments

Fineline Cube Dec 19, 2023

The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) additional indications...

Company Drug

HuidaGene Secures Rare Pediatric Disease Designation for CRISPR Therapy HG302 Targeting DMD

Fineline Cube Dec 19, 2023

HuidaGene Therapeutics, based in China, has announced that it has received Rare Pediatric Disease Designation...

Company Deals

Blue Sail Medical Partners with Weifang Government on Healthcare Initiative

Fineline Cube Dec 19, 2023

China’s Blue Sail Medical Co., Ltd. (SHE: 002382) has announced strategic cooperation agreements with the...

Company Drug

HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors

Fineline Cube Dec 19, 2023

Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the...

Company Deals

Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement

Fineline Cube Dec 19, 2023

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector,...

Company Drug

EMA’s CHMP Gives Green Light to Sanofi’s Fexinidazole for Acute Sleeping Sickness Treatment

Fineline Cube Dec 19, 2023

Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Company Medical Device

BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit

Fineline Cube Dec 19, 2023

BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced...

Company Drug

InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China

Fineline Cube Dec 19, 2023

According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382)...

Company

GSK’s CCO Calls China a Hotbed for Innovative Molecules and Licensing Deals

Fineline Cube Dec 19, 2023

In an interview with the Financial Times, Luke Miels, Chief Commercial Officer of UK-based GlaxoSmithKline...

Company Deals

Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement

Fineline Cube Dec 19, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody...

Company Deals

WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing

Fineline Cube Dec 19, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...

Company Drug

Keytruda Gains 12th Indication Approval in China for HER2-Negative Gastric Cancer

Fineline Cube Dec 19, 2023

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its immunotherapy...

Company Drug

Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study

Fineline Cube Dec 19, 2023

Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA)...

Company Drug

Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema

Fineline Cube Dec 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...

Company Drug

Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar

Fineline Cube Dec 19, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals

Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial

Fineline Cube Dec 18, 2023

Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY...

Posts pagination

1 … 458 459 460 … 696

Recent updates

  • Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
  • Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
  • Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma
  • Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression
  • Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

Company Drug

Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio

Company Drug

Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.